Clear Trail Advisors’s AbbVie ABBV Stock Holding History

Clear Trail Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3M	Buy	11,904 +2,560	+27%	+$551K	0.46%	58
2026 Q1	$2.03M	Buy	9,344 +3,488	+60%	+$774K	0.34%	62
2025 Q4	$1.34M	Buy	+5,856	New	+$1.33M	0.31%	60

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Clear Trail Advisors's ABBV Position: Q2 2026 in Review

Clear Trail Advisors increased its AbbVie (ABBV) stake by 27% in Q2 2026, buying an estimated $551K and bringing the position to 11,904 shares worth $3M. The position accounts for 0.46% of the portfolio, ranked #58.

Clear Trail Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Clear Trail Advisors held 11,904 shares of AbbVie worth $3M as of Q2 2026.
Clear Trail Advisors bought 2,560 AbbVie shares in Q2 2026, an estimated $551K.
AbbVie made up 0.46% of Clear Trail Advisors's portfolio in Q2 2026, its #58 holding.
Clear Trail Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Clear Trail Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.